ArticleScientific reports2026
Diagnostic and potential prognostic associations of long noncoding RNAs LIFR-AS1 and SLCO4A1-AS1 in multiple myeloma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
There is growing evidence for the involvement of LncRNAs in the development of multiple myeloma (MM). We aimed to investigate the possible diagnostic and potential prognostic associations of two LncRNAs with oncogenic potential, LIFR-AS1 and SLCO4A1-AS1, in MM. Using qPCR, expression levels of both LncRNAs were quantified in 30 newly diagnosed patients with MM and 30 healthy controls. Their associations with clinicopathological parameters including serum protein electrophoresis, immunofixation, bone marrow, biochemical, hematological indices and the expression of IL-17 A and RORC, downstream adaptors of the IL-17/NF-κB signaling pathway, were assessed. Diagnostic applicability was sought via ROC curve analysis. Both LncRNAs were significantly downregulated in MM patients and showed inverse correlations with IL-17 A, RORC expression, and serum IL-17 levels. Their reduced expression was also negatively correlated with β₂-microglobulin, LDH, and ESR, but positively correlated with albumin and hemoglobin (all P < 0.05). ROC analysis demonstrated potential diagnostic utility, yielding an area under the curve (AUC) of 0.691 for LIFR-AS1 (cut-off: 0.065-fold; sensitivity: 30%; specificity: 100%) and 0.711 for SLCO4A1-AS1 (cut-off: 0.805-fold; sensitivity: 80%; specificity: 100%). Our findings suggest that LIFR-AS1 and SLCO4A1-AS1 may serve as potential diagnostic relevance and prognostic associations biomarkers in MM. Further studies and warranting functional investigation are recommended to evaluate their pathogenic roles and downstream molecular interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.